Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O’day Sells 9,810 Shares of Company Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel O’Day sold 9,810 shares of the business’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $175.17, for a total value of $1,718,417.70. Following the completion of the sale, the chief executive officer directly owned 551,683 shares of the company’s stock, valued at $96,638,311.11. The trade was a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Wednesday, November 4th, Daniel O’Day sold 102,619 shares of Gilead Sciences stock. The shares were sold at an average price of $175.16, for a total value of $17,974,744.04.
• On Monday, November 2nd, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $169.74, for a total value of $2,546,100.00.
• On Friday, October 30th, Daniel O’Day sold 15,881 shares of Gilead Sciences stock. The stock was sold at an average price of $175.25, for a total value of $2,783,145.25.
• On Thursday, October 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $147.90, for a total value of $2,218,500.00.
• On Tuesday, September 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $148.64, for a total value of $2,229,600.00.

Gilead Sciences Stock Performance

Shares of GILD stock traded down $0.68 during trading hours on Friday, hitting $166.89. The stock had a trading volume of 5,817,414 shares, compared to its average volume of 6,855,866. The firm has a market capitalization of $207.00 billion, a PE ratio of -52.81 and a beta of 0.35. Gilead Sciences, Inc. has a twelve month low of $116.88 and a twelve month high of $176.58. The stock’s 50 day moving average is $152.68 and its 200 day moving average is $140.73. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 0.95.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. The business had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The company’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period last year, the firm posted $2.47 earnings per share. As a group, research analysts forecast that Gilead Sciences, Inc. will post -1.07 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.0%. Gilead Sciences’s dividend payout ratio is currently -103.80%.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: New HIV-prevention data showed twice-yearly lenacapavir achieved nearly twice the one-year treatment persistence of daily oral F/TDF, a result that could support Gilead’s long-acting HIV-prevention strategy. Article: New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence
• Positive Sentiment: In the Phase 3 IDEAL study, Livdelzi (seladelpar) achieved ALP normalization in about 75% of participants with primary biliary cholangitis. The results may strengthen its case for broader second-line use, although the stock reportedly fell following the update. Article: Gilead’s Livdelzi Achieves 75% ALP Normalization
• Positive Sentiment: Recent third-quarter results beat analyst estimates for earnings and revenue, and Gilead raised full-year product-sales guidance. The company also maintained its quarterly dividend at $0.82 per share. Article: Did Earnings Beat Just Shift Gilead Sciences’ Investment Narrative?
• Neutral Sentiment: CEO Daniel O’Day sold more than 112,000 shares across November 4–5, but the transactions were conducted under a pre-arranged Rule 10b5-1 plan. He retained 551,683 shares, which may temper concerns about the sales. SEC Form 4 filing

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Wells Fargo & Company boosted their price target on Gilead Sciences from $165.00 to $190.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $170.00 to $190.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. UBS Group increased their price objective on Gilead Sciences from $175.00 to $195.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Bank of America lifted their target price on Gilead Sciences from $168.00 to $172.00 and gave the company a “buy” rating in a research note on Tuesday, October 20th. Finally, Cantor Fitzgerald boosted their target price on Gilead Sciences from $155.00 to $175.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $170.15.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Client 1ST Advisory Group LLC boosted its stake in shares of Gilead Sciences by 4.0% during the 3rd quarter. Client 1ST Advisory Group LLC now owns 1,786 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 69 shares during the last quarter. Bfsg LLC grew its holdings in shares of Gilead Sciences by 7.7% during the third quarter. Bfsg LLC now owns 1,003 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 72 shares in the last quarter. Grove Bank & Trust grew its holdings in shares of Gilead Sciences by 1.2% during the third quarter. Grove Bank & Trust now owns 6,345 shares of the biopharmaceutical company’s stock worth $946,000 after buying an additional 74 shares in the last quarter. Financial Connections Group Inc. grew its holdings in shares of Gilead Sciences by 30.2% during the first quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 76 shares in the last quarter. Finally, Wilkerson Advisory Group LLC raised its position in shares of Gilead Sciences by 54.2% in the first quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 78 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C.

Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.